Basic Information
ID: ALA3706102
Type: Binding
Description: Radioligand Binding Assay: A bivalent ligand 1 (FIG. 14) that combines the pharmacophores of naltrexone (a MOR antagonist) and maraviroc (a CCR5 antagonist) into one molecule was designed and synthesized. Herein is reported the characterization of this novel molecular probe in for its binding affinity, Ca2− flux functional activity, and HIV-1 inhibition potency. Bivalent ligand 1 was first characterized in hMOR-expressed CHO cells in the competitive radioligand binding assay as described previously.
Organism: Homo sapiens
Cell type: CHO
Activity Charts
Bioactivity
Activity Types for Assay ALA3706102
Ki
Compound Summary
| Parent Molecular Weight | ALogP | Polar Surface Area |
|---|---|---|
| 341.41 | 1.53 | 1.53 |
| 1197.48 | ||
| 1197.48 |